Stryker Corporation $SYK Shares Purchased by CIBC Asset Management Inc

CIBC Asset Management Inc boosted its stake in Stryker Corporation (NYSE:SYK) by 55.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,951 shares of the medical technology company’s stock after acquiring an additional 34,115 shares during the period. CIBC Asset Management Inc’s holdings in Stryker were worth $33,724,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the third quarter worth $27,000. Strive Asset Management LLC acquired a new stake in shares of Stryker during the third quarter worth $30,000. CGC Financial Services LLC acquired a new stake in shares of Stryker during the fourth quarter worth $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in shares of Stryker during the third quarter worth $34,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research reports. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and set a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. BTIG Research dropped their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. UBS Group dropped their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Finally, Evercore set a $355.00 target price on shares of Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Stock Up 0.8%

SYK stock opened at $295.63 on Thursday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The firm’s 50-day simple moving average is $319.41 and its 200 day simple moving average is $346.58. The stock has a market cap of $113.33 billion, a PE ratio of 34.22, a price-to-earnings-growth ratio of 1.85 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the business earned $2.84 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.